-
1.
公开(公告)号:EP3052525A4
公开(公告)日:2017-03-29
申请号:EP14850812
申请日:2014-10-02
申请人: VIVENTIA BIO INC
IPC分类号: C07K16/30 , A61K39/395 , A61K49/00 , A61P35/00 , C07K14/21 , C07K14/415 , C07K16/46 , C07K19/00 , G01N33/574
CPC分类号: C07K16/30 , A61K39/39558 , A61K45/06 , A61K47/48438 , A61K47/48446 , A61K47/48484 , A61K47/48569 , A61K47/6817 , A61K47/6819 , A61K47/6829 , A61K47/6851 , A61K49/0002 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/92 , C07K2319/55 , G01N33/574
摘要: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab′, F(ab′)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.
摘要翻译: 本公开涉及可能缺乏T细胞表位并引发降低的免疫应答的抗体和免疫缀合物的组合物。 抗体可以是抗体片段,例如Fab,Fab',F(ab')2,scFv,dsFv,ds-scFv,二聚体,小体抗体,双抗体,双特异性抗体片段,多聚体及其任何组合。 在另一个实施方案中,抗体可以结合抗原上皮细胞粘附分子(EpCAM)。 在另一个实施方案中,免疫偶联物可以包含附着于效应分子的抗体,其中效应分子可以是放射性同位素,抗肿瘤剂,免疫调节剂,生物反应调节剂,凝集素,毒素,发色团,荧光团,化学发光 化合物,酶,金属离子及其任何组合。